Study summary · research use only
Stimulation of 2-deoxyglucose uptake in rat adipocytes by a human growth hormone fragment (hGH 4-15)
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this rat study, researchers examined effects of a human growth hormone fragment, hGH 4-15, on 2-deoxy-[1-14C]-D-glucose uptake in adipocytes in vivo and in vitro. The abstract reports a single intravenous injection of hGH 4-15 (1 mg/kg) significantly increased 2-deoxyglucose uptake in isolated cells from treated rats (p less than 0.005), and pre-incubating adipocytes from untreated rats with the hGH fragment (10 micrograms/ml) at 37 degrees C for 30 min also increased 2-deoxyglucose uptake, with and without exogenous insulin. The effect was described as concentration-dependent, with the maximum effect at 10 micrograms/ml. The authors suggest enhanced glucose transport may contribute to the hypoglycaemic action of amino-terminal fragments of human growth hormone.
Abstract
The in vivo and in vitro effects of a hypoglycaemic fragment of human growth hormone containing the sequence H2N-Ile-Pro-Leu-Ser-Arg-Leu-Phe-Asp-Asn-Ala-Met-Leu-COOH (hGH 4-15) on 2-deoxy-[1-14C]-D-glucose uptake in adipocytes were studied. The isolated cells from rats after a single intravenous injection of hGH 4-15 (1 mg/kg) significantly increased uptake of 2-deoxyglucose (p less than 0.005). Adipocytes from untreated rats pre-incubated with the hGH fragment (10 micrograms/ml) at 37 degrees C for 30 min also clearly showed an elevated uptake of 2-deoxyglucose in the absence and the presence of exogenous insulin. The effect of hGH 4-15 was concentration-dependent, steadily increasing with the maximum effect at 10 micrograms/ml. The present findings suggest that the enhancement of glucose transport in target tissues may be a major contributing factor to the hypoglycaemic action of the amino-terminal fragments of human growth hormone.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.